Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Trading Down 5.1 %

GLMD stock opened at $2.61 on Monday. The business’s 50-day moving average is $2.86 and its 200 day moving average is $3.62. The stock has a market cap of $1.68 million, a price-to-earnings ratio of -0.16 and a beta of 0.66. Galmed Pharmaceuticals has a 12-month low of $2.23 and a 12-month high of $23.80.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.